Date: 2017-01-19
Type of information: Grant
Company: Anavex Life Sciences (USA - NY)
Investors: Rettsyndrome.org (USA - OH)
Amount: $ 0.6 million
Funding type: grant
Planned used: This grant will cover the majority of a planned U.S. multicenter Phase 2 clinical trial of Anavex 2-73 for the treatment of Rett syndrome. Scheduled to begin in 2017, the trial will be a randomized, double blind, placebo-controlled study of Anavex 2-73 in patients with Rett syndrome lasting up to 12 weeks. Primary and secondary endpoints include safety as well as Rett syndrome conditions such as cognitive impairment, motor impairment, behavioral symptoms and seizure activity.
Others: * On January 19, 2017, Anavex Life Sciences and the International Rett Syndrome Foundation, doing business as Rettsyndrome.org announced that Rettsyndrome.org has committed a financial grant of a minimum of $0.6 million to cover the majority of a planned U.S. multicenter Phase 2 clinical trial of ANAVEX 2-73 for the treatment of Rett syndrome.
Therapeutic area: Neurological diseases - CNS diseases
